je.st
news
Tag: fda approval
BD Receives FDA Approval for New Automated Cervical Cancer Screening System
2016-03-09 11:31:11| Industrial Newsroom - All News for Today
Adds BD Totalys MultiProcessor and BD Totalys SlidePrep for Gynecological Specimen Preparation to Cytology Instrumentation Portfolio FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration...
Tags: system
approval
cancer
screening
Pfizer Announces FDA Approval Of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, The First And Only Once-Daily Oral JAK Inhibitor Treatment For Rheumatoid Arthritis
2016-03-02 04:30:55| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved XELJANZ XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX)
Tags: treatment
approval
oral
announces
Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
2016-01-29 00:59:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZEPATIER (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or without ribavirin (RBV), following priority review by the FDA. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
following
review
treatment
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA
2016-01-17 19:50:21| Biotech - Topix.net
Novartis announced today that the US Food and Drug Administration has approved Cosentyx for two new indications - the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis . AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine.
Tags: with
treatment
adult
approval
Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
2015-12-17 23:52:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 read more
Tags: approval
adults
surgery
induced
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »